Interleukin 6 Versus Lactic Acid in Septic Shock

November 13, 2026 updated by: Ahmed Ismail Abdelsabour, New Valley University

Interleukin 6 Versus Lactic Acid for Early Prediction and Prognosis in Septic Shock

The aim of this study is to compare between IL 6 versus lactate level for early prediction and prognosis over the first two days or 48 hours of ICU stay in patients with septic shock.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

2

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:• Adult patients aged ≥18 years.

  • Both sexes.
  • Admitted to the ICU with a diagnosis of sepsis according to Sepsis-3 criteria.
  • Presence of life-threatening organ dysfunction indicated by an increase in SOFA score of ≥ 2 points from baseline.

Exclusion Criteria:• Pregnancy.

  • Known terminal illness with expected survival rate < 24 hours.
  • Cardiopulmonary resuscitation (CPR) within 24 hours before ICU admission.
  • Chronic kidney disease requiring analysis.
  • LAC next ≥ LAC peak; Patients' medical records are insufficient.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Assessment of IL-6

The patients will have blood drawn on day 1 and day 2 of their stay in the ICU. The samples will be processed immediately;

they will be centrifuged at 3500 rpm for 10 min at 4 ◦C and frozen at -80 ◦C..

Experimental: Biochemical Assessment

Fasting blood samples will be drawn from ICU patients by venepuncture after the hemodynamic stabilization phase of admission and after 2 days of being in the ICU to measure renal function (ions and creatinine), liver function (bilirubin), nutritional parameters (folic acid, B12 and copper), hematimetric [hemoglobin, leukocytes, platelets, INR and activated partial thromboplastin time (APTT)] and inflammatory parameters [lactic acid, fibrinogen, lactate dehydrogenase (LDH)].

Fasting blood samples will be drawn from ICU patients by venepuncture after the hemodynamic stabilization phase of admission and after 2 days of being in the ICU to measure renal function (ions and creatinine), liver function (bilirubin), nutritional parameters (folic acid, B12 and copper), hematimetric [hemoglobin, leukocytes, platelets, INR and activated partial thromboplastin time (APTT)] and inflammatory parameters [lactic acid, fibrinogen, lactate dehydrogenase (LDH)]. PCR and PCT will be performed by the hospital laboratory using standard techniques.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
• Correlation between IL-6 and lactic acid.
Time Frame: 90 days
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • asyut icu 40

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.